A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

• ClinicalTrials.gov Identifier: NCT03134872
• Recruitment Status: Completed
• First Posted: May 1, 2017
• Last Update Posted: June 9, 2020
• Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Information provided by (Responsible Party): Jiangsu HengRui Medicine Co., Ltd.

Tracking Information

• First Submitted Date: April 25, 2017
• First Posted Date: May 1, 2017
• Last Update Posted Date: June 9, 2020
• Actual Study Start Date: May 12, 2017
• Actual Primary Completion Date: July 27, 2019 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 25, 2017)

• Progression-Free Survival in the intent-to-treat (ITT) population [ Time Frame: up to 24 months ]
  PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.
• Progression-Free Survival in the PD-L1-selected population [ Time Frame: up to 24 months ]
  PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: June 7, 2020)

• Overall Response Rate (ORR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Duration of Response Rate(DoR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Time To Progression (TTP) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Disease Control Rate (DCR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Overall Survival [ Time Frame: up to 24 months ]
  Defined as the time from randomization to death from any cause.
• Number of Subjects with treatment-related adverse events (AEs) [ Time Frame: up to 24 months ]
  Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.

Original Secondary Outcome Measures (submitted: April 25, 2017)

• Overall Response Rate (ORR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.
• Duration of Response Rate(DoR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Time To Progression (TTP) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Disease Control Rate (DCR) [ Time Frame: up to 24 months ]
  Determined using RECIST v1.1 criteria
• Overall Survival [ Time Frame: up to 24 months ]
  OS, defined as the time from randomization to death from any cause.
• Change from baseline in patient reported lung cancer symptoms [ Time Frame: up to 24 months ]
  Defined as time from randomization to deterioration (10 point change) on each of the EORTC QLQ-C30 and EORTC QLQ-LC13 symptom subscales (cough, dyspnea [single item and multi item subscales], chest pain, arm/shoulder pain, or fatigue) maintained for two assessments or one assessment followed by death from any cause within 3 weeks.
• Number of Subjects with treatment-related adverse events (AEs) [ Time Frame: up to 24 months ]
  Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
• Official Title: A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer

Brief Summary

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a randomized,Phase III, multicenter ,open-label study designed to evaluate the safety and efficacy of SHR-1210 with carboplatin and pemetrexed versus carboplatin-pemetrexed in subjects who are chemotherapy naive and have Stage IIIB/IV non-squamous NSCLC.

The primary hypothesis is that SHR-1210 combined with carboplatin and pemetrexed prolongs Progression Free Survival (PFS) in per RECIST 1.1 by blinded independent central review (ITT population and population was indicated by high PD-L1 expression) compared to carboplatin and pemetrexed treatment .

Detailed Description

In this study, subjects will be randomly assigned to receive either carboplatin and pemetrexed for 4-6 cycles followed by pemetrexed maintenance until progression or unacceptable toxicity, OR receive SHR-1210 combined with carboplatin and pemetrexed chemotherapy for 4-6 cycles followed by pemetrexed maintenance with SHR-1210 until progression or unacceptable toxicity (SHR-1210 for a maximum of 2 years).

Subjects assigned to the chemotherapy arm will have the opportunity to crossover to receive SHR-1210 monotherapy once they experience progression of disease (PD) defined by RECIST 1.1 and meet all the crossover criteria.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Respiratory Tract Neoplasms
• Thoracic Neoplasms
• Lung Diseases
• Respiratory Tract Disease
• Neoplasms by Site
• Neoplasm, Bronchial
• Carcinoma, Bronchogenic

Intervention

• Biological: SHR-1210
  SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
• Drug: Carboplatin
  Carboplatin
• Drug: Pemetrexed
  Pemetrexed

Study Arms

• Experimental: SHR-1210+Chemotherapy
  Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
  Interventions:

  • Biological: SHR-1210
  • Drug: Carboplatin
  • Drug: Pemetrexed
• Active Comparator: Chemotherapy
  Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
  Interventions:

  • Drug: Carboplatin
  • Drug: Pemetrexed

Publications *

• Xie Q, Zheng H, Su N, Li Q. Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. BMJ Open. 2022 Aug 5;12(8):e061592. doi: 10.1136/bmjopen-2022-061592.
• Chen T, Xie R, Zhao Q, Cai H, Yang L. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China. Front Oncol. 2022 Jul 22;12:746526. doi: 10.3389/fonc.2022.746526. eCollection 2022.
• Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 7, 2020): 419
• Original Estimated Enrollment (submitted: April 25, 2017): 412
• Actual Study Completion Date: August 29, 2019
• Actual Primary Completion Date: July 27, 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• 1. Subjects who are chemotherapy naive and have Stage IIIB-IV non-squamous NSCLC.
• 2. Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.
• 3. Fresh cutting or ≤6 months preservation specimens must be provided.
• 4. No prior systemic treatment. Subjects who have received prior neo-adjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 12 months from randomization since the last chemotherapy cycle.
• 5. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria;
• 6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
• 7. Have a life expectancy of at least 3 months.
• 8. All baseline laboratory requirements will be assessed and should be obtained within 14 days prior to the first administration of study treatment.
• 9. Female Subjects of childbearing potential must have a negative serum pregnancy test within 3 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment.
• 10. Male Subjects with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment.
• 11. Subjects has voluntarily agreed to participate by giving written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research.

Exclusion Criteria:

• 1. Target Disease Exceptions

  1. Subjects with predominantly squamous cell histology NSCLC, or SCLC.
  2. Subjects with epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) translocation.
  3. Subjects with no measurable disease by CT or MRI per RECIST 1.1 criteria.
  4. Subjects with carcinomatous meningitis, or symptoms of spinal cord compression.
  5. Subjects with active CNS metastases are excluded.
  6. Subjects who can receive surgical resection or radical radiotherapy.
  7. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

• 2. Medical History and Concurrent Diseases

  1. Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.
  2. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  3. Prior therapy with systemic immunostimulatory agents within 1 months of the first dose of trial treatment.
  4. Subjects are currently participating and receiving study therapy or had participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-value period life of the agent, before the first dose of trial treatment.
  5. Subjects who expected to require any other form of antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC).
  6. Subjects received major surgery or radiation therapy of > 30 Gy not to chest within 4 weeks of the first dose of study treatment, or radiation therapy of > 30 Gy to chest within 24 weeks of the first dose of study treatment, or radiation therapy of < 30 Gy to chest within 2 weeks of the first dose of study treatment, and had not recovered from the toxicity and/or complications of the most recent prior chemotherapy to Grade 1 or less (except alopecia or fatigue).
  7. Subjects with a history of interstitial lung disease, or other disease may interfere with the detection or treatment of suspected drug-related lung toxicity.
  8. Other active malignancy requiring concurrent intervention.
  9. Subjects with previous malignancies (except non-melanoma skin cancers, and thefollowing in situ cancers: bladder, endometrial, cervical/dysplasia) are excluded unless a complete remission was achieved at least 5 years prior to study entry.
  10. Subjects with clinically significant cardiovascular and cerebrovascular diseases.
  11. Subjects with active pulmonary tuberculosis.
  12. Subjects have severe infections within 4 weeks of the first dose of study treatment.
  13. Subjects had or plan to have allogeneic bone marrow transplantation or solid organ transplant.
  14. Subjects had administration of a live, attenuated vaccine within 30 days of the first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study.
  15. Subjects with contraindications to platinum therapy.

• 3. Physical and Laboratory Test Findings

  1. Known history of testing positive for human immunodeficiency virus (HIV) or
  2. known acquired immunodeficiency syndrome (AIDS).
  3. Known history of active Hepatitis B or C.
  4. Subjects with severe pleural effusion, pericardial effusion, or ascites need repeated drainage.
• 4. History of severe hypersensitivity reactions to other monoclonal antibodies, or intravenous infusion, or carboplatin, or pemetrexed.
• 5. Subjects have known psychiatric or substance abuse disorder (including alcohol\smoking), or be regular user (including "recreational use") of any illicit drugs that would interfere with cooperation with the requirements of the trial.
• 6. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 70 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: China

Administrative Information

• NCT Number: NCT03134872
• Other Study ID Numbers: SHR-1210-III-303-NSCLC
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
• Original Responsible Party: Same as current
• Current Study Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Wei Shi, MD; Jiangsu HengRui Medicine Co., Ltd.

• PRS Account: Jiangsu HengRui Medicine Co., Ltd.
• Verification Date: June 2020